Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

As the markets for weight-loss drugs develop, pharma companies are having to adapt in search of the next big thing.

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Walmart has agreed to pay $10 million to settle a U.S. Federal Trade Commission civil lawsuit accusing the world's largest ...

The shipments have propelled Ireland, a country of only 5.4 million people, to the second-largest goods-trade imbalance with ...

Drugmakers are racing to develop the next wave of obesity and diabetes medications that they hope will be even more powerful ...

A Chinese-developed GLP-1 drug is as effective as Ozempic or Zepbound, clinical trial says ...

“Our findings show liraglutide may be effective for treating stubborn, high-frequency migraines in patients with obesity, and ...